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ABSTRACT
The substantial heritability of most complex diseases suggests that genetic data could
provide useful risk prediction. To date the performance of genetic risk scores has
fallen short of the potential implied by heritability, but this can be explained by insuf-
ﬁcient sample sizes for estimating highly polygenic models. When risk predictors
already exist based on environment or lifestyle, two key questions are to what extent
can they be improved by adding genetic information, and what is the ultimate poten-
tial of combined genetic and environmental risk scores? Here, we extend previous
work on the predictive accuracy of polygenic scores to allow for an environmental
score that may be correlated with the polygenic score, for example when the environ-
mental factors mediate the genetic risk. We derive common measures of predictive
accuracy and improvement as functions of the training sample size, chip heritabilities
of disease and environmental score, and genetic correlation between disease and envi-
ronmental risk factors. We consider simple addition of the two scores and a weighted
sum that accounts for their correlation. Using examples from studies of cardiovascular
disease and breast cancer, we show that improvements in discrimination are generally
small but reasonable degrees of reclassiﬁcation could be obtained with current sample
sizes. Correlation between genetic and environmental scores has only minor eﬀects
on numerical results in realistic scenarios. In the longer term, as the accuracy of poly-
genic scores improves they will come to dominate the predictive accuracy compared
to environmental scores.
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1 INTRODUCTION
Predicting the individual risk of disease is one of the major
goals of epidemiology and, because most common diseases
have a heritable component, there has long been interest in
using genotype data to inform prediction of disease onset,
prognosis, or treatment response. Indeed for Mendelian disor-
ders genetic prediction has established clinical applications in
counselling, prophylactic intervention, and embryonic screen-
ing. For the common, complex disorders however, progress
has to date been slow (Abraham & Inouye, 2015; Chatterjee,
Shi, & Garcia-Closas, 2016; Jostins & Barrett, 2011). Despite
the success of genome-wide association studies (GWAS) in
identifying numerous risk variants for many disorders, these
variants typically explain a small proportion of the variation in
risk; a number of studies have examined the predictive accu-
racy of GWAS “hits” and generally found limited utility for
risk prediction (Eriksson et al., 2015; Talmud et al., 2015;
Weissfeld et al., 2015), although there have been some suc-
cesses (Maas et al., 2016; Patel et al., 2016). The reasons are
that the associated markers individually have small eﬀects on
risk, and the markers discovered to date are a small fraction
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of the total complement of risk variants. The realization that
most, perhaps all, complex traits are polygenic, that is, deter-
mined by thousands of genetic variants with small eﬀects,
has motivated a shift toward thinking about the genetic basis
of disease as a single entity (Dudbridge, 2016). Under this
paradigm, the whole genome should be regarded as a risk pre-
dictor, but attempts in this direction have so far also yielded
modest results (Evans, Visscher, & Wray, 2009; Locke et al.,
2015; Maier et al., 2015).
However, given the substantial heritability of many com-
mon disorders, it remains true that we should improve risk
prediction if we could measure the heritable component accu-
rately (Pharoah et al., 2002; Wray, Goddard, & Visscher,
2007; Wray, Yang, Goddard, & Visscher, 2010). Indeed,
a crude measure of polygenic risk, namely family history,
is already widely used as a risk predictor (Valdez, Yoon,
Qureshi, Green, & Khoury, 2010). An important insight is
that the currently disappointing performance of polygenic pre-
diction can be explained by insuﬃcient sample sizes avail-
able for estimating genetic eﬀects (Chatterjee et al., 2013;
Dudbridge, 2013). Essentially, sampling variation accumu-
lates across thousands of variants so that the polygenic predic-
tor has high measurement error even if standard errors are low
on each individual variant. However, international consortium
eﬀorts and national biobank projects are now approaching the
sizes at which accurate genetic predictors could be derived,
so the performance of genetic prediction may well improve
toward useful levels in the next few years.
Nevertheless, the heritability imposes a limit on the accu-
racy of genetic prediction, even if we knew all the variants
aﬀecting risk and their precise eﬀect sizes (Clayton, 2009).
For many disorders, this limit falls short of levels usually
regarded as clinically useful, and the only way we could
improve predictive accuracy would be by adding further non-
genetic factors into the risk score. Indeed for some conditions,
for example, cardiovascular disease (CVD) and breast can-
cer, epidemiological risk scores are already available and in
clinical use. The question then is whether inclusion of genetic
information could improve the predictive accuracy to a use-
ful degree. As with studies of genetic prediction alone, eﬀorts
to improve existing predictors by adding in genetic data have
met with only moderate success (Morris et al., 2016; Talmud
et al., 2015; Wacholder et al., 2010).
Theoretical treatments of genetic prediction have mainly
considered prediction from genotypes alone, but not the com-
mon scenario in which both genetic and nongenetic predic-
tors are combined. An exception is work of Garcia-Closas,
Gunsoy, and Chatterjee (2014), who argue that addition of
genetic data to questionnaire-based risk factors could pro-
vide useful levels of risk stratiﬁcation for breast cancer. Here,
we extend previous work on the predictive accuracy of poly-
genic risk scores (Dudbridge, 2013) to include a nonpolygenic
component. For convenience, we term all nonpolygenic risk
factors as “environmental,” although such factors could
include major genes, behavioral and other factors such as age
that arguably do not ﬁt that description. A key concern is
that many environmental risk factors are themselves herita-
ble, and may therefore mediate some or all of the genetic
risk. Indeed, comparable resources have been directed toward
GWAS of heritable risk factors such as lipid fractions (Willer
et al., 2013) and body mass index (BMI) (Locke et al., 2015)
as have been toward clinical outcomes. On the other hand,
for environments that are diﬃcult to measure well (e.g., alco-
hol consumption), it is conceivable that their heritable compo-
nent may act as a more accurate predictor of the outcome than
the measured environment itself (Verhulst, Neale, & Kendler,
2015).
Here, we show how under a quantitative genetics
model, commonly used measures of predictive accuracy and
improvement can be expressed in terms of the genetic variance
of an outcome of interest (its “chip heritability”), genetic vari-
ance of an environmental risk score, variance in the outcome
explained by the environmental score, and genetic correla-
tion between the outcome and the environmental score. These
are quantities that are readily estimated by existing methods
(Bulik-Sullivan et al., 2015; Lee, Yang, Goddard, Visscher, &
Wray, 2012), allowing examples to be drawn from recent liter-
ature to illustrate the prospects for prediction from combined
genetic and environmental factors. As in previous work (Dud-
bridge, 2013), we allow for the estimation of a polygenic risk
score from ﬁnite training data, but in contrast to other work
(Garcia-Closas et al., 2014; So & Sham, 2010), we explic-
itly consider the genetic correlation between environment and
outcome and its implications for the computation of combined
risk scores.
2 MATERIALS AND METHODS
2.1 Quantitative Model
Consider two linear models for an outcome Y, the ﬁrst in terms
of a scalar environmental factor X:
𝐸(𝑌 ) = 𝑋
the second in terms of m genetic markers:
𝐸(𝑌 ) = 𝜷′G =
𝑚∑
𝑖=1
𝛽𝑖𝐺𝑖,
where 𝛽 is an m-vector of coeﬃcients 𝛽𝑖. Assume that the
eﬀect of the environmental factor X on Y is known precisely,
so that without loss of generality X may be assumed to have a
unit eﬀect on Y. Denote by 𝑅2
𝑋𝑌
the proportion of variance in
Y explained by X. Assuming also that Y is standardized, then
var(𝑋) = 𝑅2
𝑋𝑌
.
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Assume that genotypes G are independent (i.e.,
in linkage equilibrium) and standardized. Thus, for
single nucleotide polymorphisms (SNPs) in Hardy–
Weinberg equilibrium, the usual additive coding gives
𝐺𝑖 = (𝐴𝑖 − 2𝑓𝑖)∕(2𝑓𝑖(1 − 𝑓𝑖))1∕2, where 𝐴𝑖 is the number
of minor alleles and 𝑓𝑖 is the minor allele frequency at
SNP 𝑖. The genetic eﬀects 𝛽𝑖 are regarded as ﬁxed across
samples, but random over 𝑖 = 1,… , 𝑚 with 𝐸(𝛽𝑖) = 0,
var(𝛽𝑖) = 𝑚−1𝜎2𝐺. Then the genetic variance of Y is 𝜎
2
𝐺
, and
because Y is standardized the chip heritability of markers G,
denoted by 𝑅2
𝐺𝑌
, is equal to 𝜎2
𝐺
.
The separate marginal genetic and environmental models
for Y reﬂect common practice in ﬁtting such models. Many
environmental risk factors have been extensively studied prior
to the genomics era, and accurate estimates of their eﬀects
have been obtained from large epidemiological studies with-
out adjustment for genetic factors. Here it is assumed that the
environmental eﬀect size is known with negligible standard
error so that we may ignore sampling error in the eﬀect of X.
Genetic eﬀect sizes are often estimated by large consortia
in which it may be impractical to adjust for any but the sim-
plest risk factors (e.g., age and sex) across contributing stud-
ies. However, estimation of the marginal genetic eﬀects is a
key determinant of predictive accuracy. Let the genetic eﬀects
be estimated from a training sample of size n with the poly-
genic risk score then deﬁned by:
?̂? = 𝛽′G.
For ordinary least squares estimates of 𝛽, Dudbridge
(Dudbridge, 2013) showed that:
cov(?̂?, 𝑌 ) = 2𝑅2
𝐺𝑌
[
Φ(𝑟0) − Φ(𝑟1) + 𝑟1𝜑(𝑟1) − 𝑟0𝜑(𝑟0)
]
,
(1)
var(?̂?) = 2𝑚𝜋0𝑛−1
[
Φ(𝑞0) − Φ(𝑞1) + 𝑞1𝜑(𝑞1) − 𝑞0𝜑(𝑞0)
]
+2𝑚(1 − 𝜋0)((1 − 𝜋0)−1𝑚−1𝑅2𝐺𝑌 + 𝑛
−1)[
Φ(𝑟0) − Φ(𝑟1) + 𝑟1𝜑(𝑟1) − 𝑟0𝜑(𝑟0)
]
,
(2)
where 𝜋0 is a proportion of markers assumed to have
no eﬀect (𝛽𝑖 = 0), with the rest assumed to have eﬀects
following a normal distribution; 𝑞0 = Φ−1(1 −
1
2𝑝0),
𝑞1 = Φ−1(1 −
1
2𝑝1), where 𝑝0, 𝑝1 are lower and upper
two-tailed P-values to select markers into the poly-
genic score; and 𝑟0 = 𝑞0(𝑛(1 − 𝜋0)−1𝑚−1𝑅2𝐺𝑌 + 1)
−12 ,
𝑟1 = 𝑞1(𝑛(1 − 𝜋0)−1𝑚−1𝑅2𝐺𝑌 + 1)
−12 .
Now consider a polygenic component to the environmen-
tal factor X. Denote the chip heritability of X by 𝑅2
𝐺𝑋
and the
genetic correlation between X and Y by 𝜌. That is, 𝜌 is the cor-
relation between the 𝛽𝑖 and the corresponding genetic eﬀects
onX: thus it is a property of themarkers G and should properly
be called a chip correlation. Then the chip covariance between
X and Y is:
𝜌
√
𝑚−2𝑅2
𝐺𝑌
𝑅2
𝑋𝑌
𝑅2
𝐺𝑋
and so
cov(𝑆,𝑋) = 𝑚𝜌
√
𝑚−2𝑅2
𝐺𝑌
𝑅2
𝑋𝑌
𝑅2
𝐺𝑋
= 𝜌
√
𝑅2
𝐺𝑌
𝑅2
𝑋𝑌
𝑅2
𝐺𝑋
.
The covariance of the estimated polygenic score ?̂? with
the environmental score X also follows from the results of
Dudbridge:
cov(?̂?, 𝑋) = 2cov(𝑆,𝑋)
[
Φ(𝑟0)−Φ(𝑟1) + 𝑟1𝜑(𝑟1)−𝑟0𝜑(𝑟0)
]
= 2𝜌
√
𝑅2
𝐺𝑌
𝑅2
𝑋𝑌
𝑅2
𝐺𝑋
[
Φ(𝑟0) − Φ(𝑟1) + 𝑟1𝜑(𝑟1)
−𝑟0𝜑(𝑟0)
]
. (3)
Now consider a combined score formed as the weighted
sum of polygenic and environmental scores:
?̂?𝑐𝑜𝑚𝑏 = 𝑤1?̂? +𝑤2𝑋. (4)
The coeﬃcient of determination for the combined score is:
𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
=
cov(?̂?𝑐𝑜𝑚𝑏, 𝑌 )
2
var(?̂?𝑐𝑜𝑚𝑏)
, (5)
where
cov(?̂?𝑐𝑜𝑚𝑏, 𝑌 ) = 𝑤1cov(?̂?, 𝑌 ) +𝑤2𝑅2𝑋𝑌 , (6)
var(?̂?𝑐𝑜𝑚𝑏) = 𝑤21var(?̂?) +𝑤
2
2𝑅
2
𝑋𝑌
+ 2𝑤1𝑤2cov(?̂?, 𝑋). (7)
A simple choice of weights just adds the two scores
together,𝑤1 = 𝑤2 = 1. Although this seems naive when there
is genetic correlation between X and Y, it is a very commonly
used approach. A better choice is to take the ordinary least
squares solution to the linear model:
𝐸(𝑌 ) = ?̂?𝑐𝑜𝑚𝑏,
which is[
𝑤1
𝑤2
]
=
[
var(?̂?) cov(?̂?, 𝑋)
cov(?̂?, 𝑋) var(𝑋)
]−1 [cov(?̂?, 𝑌 )
cov(𝑋, 𝑌 )
]
=
[
var(?̂?) cov(?̂?, 𝑋)
cov(?̂?, 𝑋) 𝑅2
𝑋𝑌
]−1 [cov(?̂?, 𝑌 )
𝑅2
𝑋𝑌
]
.
To summarize thus far, the coeﬃcient of determination
for the combined score is expressed in terms of the genetic
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TABLE 1 Parameters and Notation of Polygenic Model
Design Parameters Interpretation
n Training sample size
m Total number of independent markers in
genotyping panel
p0, p1 Lower and upper P values to select
markers into polygenic score
Genetic model parameters
𝑅2
𝐺𝑌
Variance in Y explained by genotypes G;
chip heritability of Y
𝑅2
𝑋𝑌
Variance in Y explained by environment X
𝑅2
𝐺𝑋
Variance in X explained by genotypes G;
chip heritability of X
𝜌 Genetic (chip) correlation between X and
Y
𝜋0 Proportion of markers with no eﬀect on Y
model parameters listed in Table 1 and the derived quanti-
ties cov(?̂?, 𝑌 ), var(?̂?), and cov(?̂?, 𝑋) (Equations (1), (2), and
(3)). For continuous Y, this coeﬃcient of determination is the
R2 between predicted and observed traits, a common measure
of predictive accuracy.
2.2 Binary Outcomes
For binary outcomes, the liability threshold (or probit) model
closely approximates the linear model for the small eﬀects
expected on polygenic traits, and allows several measures of
predictive accuracy to be expressed analytically (So & Sham,
2010). Let Y now be an unobserved liability, distributed as
standard normal, with the binary outcome D = 1 when Y
exceeds a ﬁxed threshold 𝜏, 0 otherwise. Denote by K the
prevalence of the trait and by P the case/control sampling
ratio in the training data, deﬁned to equal K in a prospec-
tive study. The variance of the observed D in the training data
is 𝑃 (1 − 𝑃 ) and eﬀects on Y are transformed to eﬀects on D
by the factor 𝑐 = 𝝋(𝜏) 𝑃 (1−𝑃 )
𝐾(1−𝐾) (Lee, Wray, Goddard, & Viss-
cher, 2011). Let ?̂? now be the polygenic score with eﬀects
estimated on the observed D and transformed back to the
liability scale by 𝑐−1. Then analogous to Equations (1), (2),
and (3),
cov(?̂?, 𝑌 ) = 2𝑅2
𝐺𝑌
[
Φ(𝑟0) − Φ(𝑟1) + 𝑟1𝜑(𝑟1) − 𝑟0𝜑(𝑟0)
]
,
var(?̂?) = 𝑐−22𝑚𝜋0𝑃 (1 − 𝑃 )𝑛−1[
Φ(𝑞0) − Φ(𝑞1) + 𝑞1𝜑(𝑞1) − 𝑞0𝜑(𝑞0)
]
+2𝑚𝑐−2(1 − 𝜋0)((1 − 𝜋0)−1𝑚−1𝑐2𝑅2𝐺𝑌
+𝑃 (1 − 𝑃 )𝑛−1)
[
Φ(𝑟0) − Φ(𝑟1) + 𝑟1𝜑(𝑟1)
− 𝑟0𝜑(𝑟0)
]
,
where now
𝑟0 = 𝑞0(𝑛𝑃−1(1 − 𝑃 )−1(1 − 𝜋0)−1𝑚−1𝑐2𝑅2𝐺𝑌 + 1)
−12 ,
𝑟1 = 𝑞1(𝑛𝑃−1(1 − 𝑃 )−1(1 − 𝜋0)−1𝑚−1𝑐2𝑅2𝐺𝑌 + 1)
−12 .
The combined score ?̂?𝑐𝑜𝑚𝑏 is calculated as before from
Equation (4) and its coeﬃcient of determination𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
from
Equations (5), (6), and (7).
2.3 Area under ROC Curve
The accuracy of predicting a binary outcome is often assessed
by the area under the receiver operator characteristic curve
(AUC), which measures the discrimination concordance
between risk scores and outcomes. That is, AUC is the prob-
ability that a subject with the trait has a higher risk score than
a subject without the trait. The central limit theorem implies
that the polygenic score ?̂? is normally distributed. Assuming
that the environmental score X also is normally distributed:
𝐴𝑈𝐶 = Φ
⎛⎜⎜⎜⎝
𝐸(?̂?𝑐𝑜𝑚𝑏|𝐷 = 1) − 𝐸(?̂?𝑐𝑜𝑚𝑏|𝐷 = 0)√
var(?̂?𝑐𝑜𝑚𝑏|𝐷 = 1) + var(?̂?𝑐𝑜𝑚𝑏|𝐷 = 0)
⎞⎟⎟⎟⎠ , (8)
where
𝐸(?̂?𝑐𝑜𝑚𝑏|𝐷 = 1) = 𝜑(𝜏)
𝐾
𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
,
var(?̂?𝑐𝑜𝑚𝑏|𝐷 = 1)
= 𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
[
1 − 𝜑(𝜏)
𝐾
𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
(
𝜑(𝜏)
𝐾
− 𝜏
)]
,
𝐸(?̂?𝑐𝑜𝑚𝑏|𝐷 = 0) = −𝜑(𝜏)1 −𝐾 𝑅2?̂?𝑐𝑜𝑚𝑏𝑌 ,
var(?̂?𝑐𝑜𝑚𝑏|𝐷 = 0)
= 𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
[
1 − 𝜑(𝜏)
1 −𝐾
𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
(
𝜑(𝜏)
𝐾
+ 𝜏
)]
.
Full derivations of these equalities have been provided pre-
viously (Dudbridge, 2013; So & Sham, 2010; Wray et al.,
2010).
2.4 Net Reclassification Index
The AUC has some limitations that have been well docu-
mented (Cook, 2007), notably that it reﬂects only the rank-
ing of subjects, but not their absolute risk levels. Further-
more, substantial increases in AUC may be hard to achieve
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even with the addition of informative markers. This has led to
the proposal of new measures of incremental predictive accu-
racy, of which the net reclassiﬁcation improvement (NRI) has
proved popular (Pencina, D'Agostino, D'Agostino, & Vasan,
2008). Given discrete risk categories deﬁned by absolute risk
thresholds, the NRI compares the classiﬁcation of subjects
under an initial risk predictor to their reclassiﬁcation under an
augmented predictor including an additional marker. Specif-
ically, the NRI is calculated in cases as the proportion cor-
rectly reclassiﬁed to a higher risk category minus the pro-
portion incorrectly reclassiﬁed to a lower category. Similarly,
the NRI is calculated in controls as the proportion correctly
reclassiﬁed to a lower category minus the proportion incor-
rectly reclassiﬁed to a higher category. The case and control
NRI could be combined into an overall NRI (Kerr et al., 2014;
Pencina, D'Agostino, & Steyerberg, 2011).
Currently, there is substantial interest in whether a poly-
genic risk score adds worthwhile information to an existing
environmental score. Under the liability threshold model, the
NRI can be calculated from tail probabilities of the joint dis-
tribution of liability, environmental, and combined scores (So
& Sham, 2010). Here the calculation is adjusted to allow for
chip correlation between environment X and liability Y.
Consider two categories of risk deﬁned by a threshold a.
(This calculation can be extended if desired to a greater num-
ber of categories.) Under the liability thresholdmodel, the risk
for environmental score X is:
1 − Φ
⎛⎜⎜⎜⎝
𝜏 −𝑋√
1 −𝑅2
𝑋𝑌
⎞⎟⎟⎟⎠ (9)
and so the risk equals the threshold a when
𝑋 = 𝑎𝑋 = 𝜏 −
√
1 −𝑅2
𝑋𝑌
Φ−1(1 − 𝑎).
The combined score, though constructed as an estimate of
liability, may have variance diﬀering from 1 depending on the
choice of the weights 𝑤1, 𝑤2. To obtain absolute risks from
the combined score, it is therefore calibrated to the liability by
rescaling by its regression coeﬃcient on Y:
𝛾 =
cov(?̂?𝑐𝑜𝑚𝑏, 𝑌 )
var(?̂?𝑐𝑜𝑚𝑏)
calculated from Equations (6) and (7), so that
var(𝛾?̂?𝑐𝑜𝑚𝑏) =
cov(?̂?𝑐𝑜𝑚𝑏, 𝑌 )
2
var(?̂?𝑐𝑜𝑚𝑏)
= 𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
.
(The least squares solutions of 𝑤1, 𝑤2 do give 𝛾 = 1.) The
risk equals the threshold a when
𝛾?̂?𝑐𝑜𝑚𝑏 = 𝑎𝑆 = 𝜏 −
√
1 − 𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
Φ−1(1 − 𝑎).
Again assuming that both polygenic and environmental
scores are normally distributed, the joint distribution of liabil-
ity, X, and the calibrated combined score is trivariate normal
with mean zero and variance-covariance matrix:
⎡⎢⎢⎢⎢⎣
1 𝑅2
𝑋𝑌
𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
𝑅2
𝑋𝑌
𝑅2
𝑋𝑌
cov(𝛾?̂?𝑐𝑜𝑚𝑏,𝑋)
𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
cov(𝛾?̂?𝑐𝑜𝑚𝑏,𝑋) 𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
⎤⎥⎥⎥⎥⎦
,
where
cov(𝛾?̂?𝑐𝑜𝑚𝑏,𝑋) = 𝛾(cov(?̂?, 𝑋) +𝑅2𝑋𝑌 )
is calculated using Equation (3).
The case NRI is:
Pr(𝛾?̂?𝑐𝑜𝑚𝑏 > 𝑎𝑆,𝑋 ≤ 𝑎𝑋|𝐷 = 1)
−Pr(𝛾?̂?𝑐𝑜𝑚𝑏 ≤ 𝑎𝑆,𝑋 > 𝑎𝑋|𝐷 = 1),
where
Pr(𝛾?̂?𝑐𝑜𝑚𝑏 > 𝑎𝑆,𝑋 ≤ 𝑎𝑋|𝐷 = 1)
=
∞
∫
𝜏
𝑎𝑋
∫
−∞
∞
∫
𝑎𝑆
𝜑3(𝑙, 𝑥, 𝑠)𝑑𝑠𝑑𝑥𝑑𝑙∕𝐾,
Pr(𝛾?̂?𝑐𝑜𝑚𝑏 ≤ 𝑎𝑆,𝑋 > 𝑎𝑋|𝐷 = 1)
=
∞
∫
𝜏
∞
∫
𝑎𝑋
𝑎𝑆
∫
−∞
𝜑3(𝑙, 𝑥, 𝑠)𝑑𝑠𝑑𝑥𝑑𝑙∕𝐾,
𝜑3 being the trivariate normal density function just deﬁned.
Similarly the control NRI is:
Pr(𝛾?̂?𝑐𝑜𝑚𝑏 ≤ 𝑎𝑆,𝑋 > 𝑎𝑋|𝐷 = 0)
−Pr(𝛾?̂?𝑐𝑜𝑚𝑏 > 𝑎𝑆,𝑋 ≤ 𝑎𝑋|𝐷 = 0),
where
Pr(𝛾?̂?𝑐𝑜𝑚𝑏 ≤ 𝑎𝑆,𝑋 > 𝑎𝑋|𝐷 = 0)
=
𝜏
∫
−∞
∞
∫
𝑎𝑋
𝑎𝑆
∫
−∞
𝜑3(𝑙, 𝑥, 𝑠)𝑑𝑠𝑑𝑥𝑑𝑙∕(1 −𝐾),
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Pr(𝛾?̂?𝑐𝑜𝑚𝑏 > 𝑎𝑆,𝑋 ≤ 𝑎𝑋|𝐷 = 0)
=
𝜏
∫
−∞
𝑎𝑋
∫
−∞
∞
∫
𝑎𝑆
𝜑3(𝑙, 𝑥, 𝑠)𝑑𝑠𝑑𝑥𝑑𝑙∕(1 −𝐾).
2.5 Continuous NRI and IDI
The discrete categories used in the NRI may be a limitation
when such thresholds have not been ﬁxed in practice or when
comparing predictors between studies with diﬀerent charac-
teristics. Two alternatives that do not rely on discrete cate-
gories are the continuous NRI (Pencina et al., 2011) and the
integrated discrimination improvement (IDI) (Pencina et al.,
2008).
In cases, the continuous NRI is the proportion whose risk
score increases under the augmented predictor minus the pro-
portion whose score decreases. Similarly in the controls it is
the proportion whose risk score decreases minus that whose
score increases. Therefore, in cases the continuous NRI is:
Pr(𝛾?̂?𝑐𝑜𝑚𝑏 > 𝑋|𝐷 = 1) − Pr(𝛾?̂?𝑐𝑜𝑚𝑏 ≤ 𝑋|𝐷 = 1)
= 2 Pr(𝛾?̂?𝑐𝑜𝑚𝑏 > 𝑋|𝐷 = 1) − 1,
where
Pr(𝛾?̂?𝑐𝑜𝑚𝑏 > 𝑋|𝐷 = 1) = ∞∫
𝜏
∞
∫
0
𝜑2(𝑙, 𝑥)𝑑𝑥𝑑𝑙∕𝐾
with 𝜑2 the bivariate normal density of liability and 𝛾?̂?𝑐𝑜𝑚𝑏 −
𝑋. This distribution has mean 0 and variance-covariance
matrix:
⎡⎢⎢⎣
1 𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
−𝑅2
𝑋𝑌
𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
− 𝑅2
𝑋𝑌
𝑅2
?̂?𝑐𝑜𝑚𝑏𝑌
+𝑅2
𝑋𝑌
− 2cov(𝛾?̂?𝑐𝑜𝑚𝑏,𝑋)
⎤⎥⎥⎦ .
Similarly in controls, the continuous NRI is:
2
𝜏
∫
−∞
0
∫
−∞
𝜑2(𝑙, 𝑥)𝑑𝑥𝑑𝑙∕(1 −𝐾) − 1.
The IDI is the mean change in risk among cases minus the
mean change in controls:
𝐸
?̂?𝑐𝑜𝑚𝑏
⎡⎢⎢⎣1 − Φ
⎛⎜⎜⎝ 𝜏−𝛾?̂?𝑐𝑜𝑚𝑏√1−𝑅2?̂?𝑐𝑜𝑚𝑏𝑌
⎞⎟⎟⎠ |𝐷 = 1
⎤⎥⎥⎦ − 𝐸𝑋
[
1 − Φ
(
𝜏−𝑋√
1−𝑅2
𝑋𝑌
)|𝐷 = 1]
−𝐸
?̂?𝑐𝑜𝑚𝑏
⎡⎢⎢⎣1 − Φ
⎛⎜⎜⎝ 𝜏−𝛾?̂?𝑐𝑜𝑚𝑏√1−𝑅2?̂?𝑐𝑜𝑚𝑏𝑌
⎞⎟⎟⎠ |𝐷= 0
⎤⎥⎥⎦ + 𝐸𝑋
[
1 − Φ
(
𝜏−𝑋√
1−𝑅2
𝑋𝑌
)|𝐷= 0]
=
∞∫
−∞
Φ
⎛⎜⎜⎝ 𝜏−𝑙√1−𝑅2?̂?𝑐𝑜𝑚𝑏𝑌
⎞⎟⎟⎠
[
𝜑
(
𝑙−𝐸(𝛾?̂?𝑐𝑜𝑚𝑏|𝐷=0)√
var(𝛾?̂?𝑐𝑜𝑚𝑏|𝐷=0)
)
− 𝜑
(
𝑙−𝐸(𝛾?̂?𝑐𝑜𝑚𝑏|𝐷=1)√
var(𝛾?̂?𝑐𝑜𝑚𝑏|𝐷=1)
)]
𝑑𝑙
−
∞∫
−∞
Φ
(
𝜏−𝑙√
1−𝑅2
𝑋𝑌
)[
𝜑
(
𝑙−𝐸(𝑋|𝐷=0)√
var(𝑋|𝐷=0)
)
− 𝜑
(
𝑙−𝐸(𝑋|𝐷=1)√
var(𝑋|𝐷=1)
)]
𝑑𝑙
,
G
X
Y
E
F IGURE 1 Directed acyclic graph showing correlation between
polygenic and environmental scores arising from mediation
Note: G: polygenic score; E: nongenetic risk factors; X: environmental
risk score; Y: outcome.
where the conditional means and variances have been
obtained previously for calculation of AUC.
3 RESULTS
3.1 Cardiovascular Disease
The analytic results are now compared to some published
studies of the predictive improvement from genotype data. In
many countries, lipid lowering medication is advised for sub-
jects whose medium term risk of a coronary event exceeds
a threshold (Goﬀ et al., 2014; JBS3 Board, 2014). Environ-
mental risk scores have been developed using data from lon-
gitudinal studies, including the American College of Cardi-
ology/American Heart Association Score (Goﬀ et al., 2014),
Framingham Risk Score (FRS) (D'Agostino et al., 2008),
and QRISK-2 equation (Hippisley-Cox, Coupland, Robson,
& Brindle, 2010). Risk factors commonly included are age,
gender, components of total cholesterol, smoking, BMI, and
blood pressure. A 10-year risk of 20% has been traditionally
used as a threshold although recent guidelines have suggested
lower thresholds, thus widening the prescription of such
medications, primarily statins (Hippisley-Cox et al., 2010).
Figure 1 is a directed acyclic graph illustrating how the envi-
ronmental risk score mediates some of the genetic risk, while
also including nongenetic factors.
Several studies have assessed the incremental value of a
limited number of SNPs compared to traditional risk fac-
tors (Hughes et al., 2012; Morrison et al., 2007; Thanas-
soulis et al., 2012; Tikkanen, Havulinna, Palotie, Salomaa, &
Ripatti, 2013). In general, very small improvements in AUC
have been observed, but some promise has been identiﬁed
for reclassiﬁcation, particularly for individuals at intermedi-
ate risk. It is indeed those individuals who may be reluctant
to adopt a medication and thus for whom accurate risk predic-
tion is desirable. Two recent studies have used genome-wide
signiﬁcant SNPs from the CARDIoGRAMplusC4D consor-
tium (Deloukas et al., 2013), the largest study yet conducted
in CVD, representing the state of the art in terms of the num-
ber of signiﬁcantly associated SNPs and the precision of their
estimated eﬀects.
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de Vries et al. (2015) considered prediction of coronary
heart disease (CHD) in the Rotterdam Study using 49 SNPs
signiﬁcant at 𝑃 < 5 × 10−8 and with 152 SNPs signiﬁcant at
approximately 𝑃 < 10−3. Improvements over traditional risk
factors were small: for example, in comparison to an envi-
ronmental score including established risk factors, the AUC
improved from 0.716 to 0.718 and the total NRI was 0.014
across four risk categories using the 49 SNP score. For the 152
SNP score theAUC improved to 0.719 and theNRIwas 0.022.
Morris et al. (2016) considered prediction of CVD (deﬁned
as CHD or stroke) in the UCLEB consortium using the same
49 SNPs with 𝑃 < 5 × 10−8 and three additional SNPs like-
wise associated with stroke. In comparison with the QRISK-
2 score, the AUC actually decreased from 0.635 to 0.623,
whereas the NRI was 0.0025 for a 10-year risk of 10%.
In a further recent study, Abraham et al. (2016) used all
the SNPs genotyped in CARDIoGRAMplusC4D with some
pruning by linkage disequilibrium. Over two target samples,
AUC improved by approximately 0.016 and the continuous
NRI over the FRS was between 0.147 and 0.195 in cases, and
between 0.102 and 0.175 in controls.
The present model is diﬃcult to ﬁt to these studies because
the full CARDIoGRAMplusC4D sample was genotyped on
the MetaboChip, a targeted array of approximately 200,000
SNPs chosen on the basis of prior association with several
cardio-metabolic disorders. The genomic coverage and chip
heritability of this array falls short of a full GWAS array; the
proportion of null SNPs may be lower than in a full array, but
the distribution of eﬀect sizes will exhibit selection bias. The
published list of SNP eﬀects used by these recent studies con-
sists of 79,138 SNPs present on both GWAS and MetaboChip
products. To simplify the presentation, it is assumed that a
full GWAS array was used, which could be approximated by
100,000 independent SNPs. A genetic model was identiﬁed
that closely matches the results of Morris et al. (2016), which
were more readily compared to the present theory than were
those of the other studies. Although this model may depart
from the truth, it will serve the main aim of illustrating the
eﬀects of marker selection and sample size on the incremen-
tal accuracy.
The training data from CARDIoGRAMplusC4D include
63,746 cases and 130,681 controls. Taking the chip heritabil-
ity of CHD as 𝑅2
𝐺𝑌
= 0.3, proportion of null SNPs 𝜋0 = 0.8
and disease prevalence 𝐾 = 0.15 gives an expected AUC of
0.536 when SNPs are selected by 𝑃 < 5 × 10−8, similar to
the result of Morris et al. For the environmental score, the
chip heritability of FRS, which includes similar risk factors to
QRISK-2, is approximately 0.3 (Simonson, Wills, Keller, &
McQueen, 2011). To obtain an AUC of 0.635, as per QRISK-
2 in Morris et al., Equation (8) implies 𝜎2
𝑋
= 0.052.
With these parameters, and selecting SNPs into the score
by 𝑃 < 5 × 10−8, Equation (8) gives AUC of 0.622 for the
unweighted combined score when 𝜌 = 0.1, or AUC of 0.621
when 𝜌 = 0.4, both lower than the AUC of 0.635 for the envi-
ronmental score alone and consistent with the results of Mor-
ris et al. The least squares weighted score gives AUC of 0.623
and 0.622, respectively. Such a decrease in AUC is a known
eﬀect when adding in a weakly predictive marker (Pepe, Fan,
Feng, Gerds, & Hilden, 2015). However, the present theory
suggests that the predictive accuracy of the unweighted score
would be maximized when selecting SNPs by P < 0.033, giv-
ing AUC of 0.693; for the weighted score, the AUC would be
0.700 when P < 0.053. Clearly, in contrast to common prac-
tice, predictive accuracy is improved by more liberal selection
of SNPs into the polygenic score. These results are summa-
rized in Table 2, which also shows that under these parame-
ters, AUC of nearly 0.8 could be achieved by the polygenic
score with a very large training sample and improved only
slightly by the environmental score. Supplementary Table S1
shows results with the prevalence reduced to 0.06, and Table 3
with the proportion of null SNPs increased to 0.95 (Palla
& Dudbridge, 2015), both cases showing modest increase in
AUC with similar qualitative conclusions.
Figures 2 and 3 show the expected AUC as a function
of training sample size for the unweighted and least squares
weighted scores. Notably, the results are almost identical for
unweighted and weighted scores except at low training sample
sizes. Although at a given sample size the degree of genetic
correlation has small eﬀects on AUC, it can have a strong
bearing on the sample size required to reach a critical level of
AUC. For example, to reach AUC of 0.75, the required sam-
ple size is approximately 159,000 when 𝜌 = 0.1 but 210,000
when 𝜌 = 0.4, and 284,000 for the polygenic score alone. The
curves level out at around 200,000 cases, beyond which fur-
ther gains are small. The CARDIoGRAMplusC4D consor-
tium has recently exceeded this sample size and its predic-
tion studies, when completed, will allow further reﬁnement
of these projections.
Table 3 shows expected NRI for 𝑃 < 5 × 10−8 and for opti-
mal thresholds at a single risk threshold of 10%. Morris et al.
reported a case NRI of− 0.0207 and control NRI of 0.0233 for
an unweighted combined score, each slightly larger in magni-
tude than predicted here but compatible in direction and with
sampling error. Substantially larger NRI is possible with more
liberal selection of SNPs, and also with a larger training sam-
ple. The improvements are largely within the controls, unaf-
fected individuals correctly reclassiﬁed to lower risk by addi-
tion of the polygenic score. Supplementary Tables S3 and S4
show results for alternative values of the prevalence and pro-
portion of null SNPs.
Table 4 shows results for the weighted score and 𝜌 = 0.4
for the higher risk threshold of 20% and for the continu-
ous NRI and IDI. Results (not shown) are similar for the
unweighted score or 𝜌 = 0.1. Again, substantial improve-
ments are possible, though the gains now appear concentrated
among cases. Supplementary Tables S5 and S6 show results
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TABLE 2 AUC for environmental score, polygenic score, and combined scores based on a genetic model matching results for CVD reported by
Morris et al
Environment Polygenic Unweighted Sum Weighted Sum
N cases 𝝆 = 0.1 𝝆 = 0.4 𝝆 = 0.1 𝝆 = 0.4
63,746 0.635 0.536 (5× 10−8) 0.622 (5× 10−8) 0.621 (5 × 10−8) 0.623 (5 × 10−8) 0.622 (5 × 10−8)
63,746 0.635 0.666 (0.053) 0.693 (0.033) 0.688 (0.036) 0.701 (0.053) 0.693 (0.053)
∞ 0.635 0.782 0.800 0.784 0.800 0.788
In parentheses, P-value thresholds to select SNPs into polygenic score; N cases, number of cases in training sample with 2.05 controls per case as in CARDIoGRAM-
plusC4D.
TABLE 3 NRI for a single risk threshold of 10% for combined scores based on a genetic model matching results for CVD reported by Morris
et al
Unweighted Sum Weighted Sum
N cases 𝝆 = 0.1 𝝆 = 0.4 𝝆 = 0.1 𝝆 = 0.4
Case Control Case Control Case Control Case Control
63,746 − 0.0049 0.012 − 0.0038 0.0095 − 0.0060 0.015 0.0053 0.013
63,784 − 0.046 (0.79) 0.186 (0.031) − 0.045 (0.76) 0.176 (0.031) − 0.052 (0.85) 0.2 (0.056) − 0.049 (0.86) 0.186 (0.059)
∞ − 0.046 0.367 − 0.050 0.344 − 0.046 0.368 − 0.049 0.349
In parentheses, P-value thresholds to select SNPs into polygenic score; N cases, number of cases in training sample with 2.05 controls per case as in CARDIoGRAM-
plusC4D.
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F IGURE 2 AUC of unweighted combined score as a function of
training sample size
Note: Genetic model chosen to match results for CVD reported by Mor-
ris et al., with 2.05 controls per case as in the CARDIoGRAMplusC4D
consortium. Rho: chip correlation between environment and outcome.
Gene: polygenic score alone. Environment: environmental score alone.
for alternative values of the prevalence and proportion of null
SNPs.
Note that at ﬁnite sample size, the optimal P-value thresh-
old varies according to the risk threshold and whether the case
or control NRI is maximized, and those thresholds are not the
ones that maximize AUC. Although the values of NRI are not
greatly changed by using the threshold that maximizes AUC,
this shows that the optimal genetic predictor can depend on the
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F IGURE 3 AUC of weighted combined score as a function of
training sample size
Note: Genetic model chosen to match results for CVD reported by Mor-
ris et al, with 2.05 controls per case as in the CARDIoGRAMplusC4D
consortium. Rho: chip correlation between environment and outcome.
Gene: polygenic score alone. Environment: environmental score alone.
chosen measure of accuracy. However, the optimal threshold
is the same for continuous NRI and IDI as it is for AUC.
For this model, the optimal threshold to select SNPs at
the CARDIoGRAMplusC4D sample size is at approximately
nominal signiﬁcance. Although this is well short of genome-
wide signiﬁcance, it results in fewer than 5,000 expected type-
1 errors from 100,000 tests and an expected false discovery
rate of about 0.4. It is this false discovery rate, rather than
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TABLE 4 NRI for a single-risk threshold of 20%, continuous NRI and IDI for combined scores based on a genetic model matching results for
CVD reported by Morris et al
20% Risk Continuous NRI IDI
N cases Case Control Case Control
63,784 0.014 − 0.006 0.080 0.014 0.0018
63,784 0.187 (0.048) − 0.054 (0.76) 0.369 (0.053) 0.065 (0.053) 0.042 (0.053)
∞ 0.347 − 0.058 0.631 0.111 0.135
In parentheses, P-value thresholds to select SNPs into polygenic score; N cases, number of cases in training sample with 2.05 controls per case as in CARDIoGRAM-
plusC4D.
TABLE 5 AUC for environmental score, polygenic score and combined scores based on a genetic model matching results for breast cancer
reported by Mavaddat et al
Environment Polygenic 𝑹𝟐
𝑮𝑿
= 𝟎.𝟏 𝑹𝟐
𝑮𝑿
= 𝟎.𝟖
N cases 𝝆 = 𝟎.𝟏 𝝆 = 𝟎.𝟒 𝝆 = 𝟎.𝟏 𝝆 = 𝟎.𝟒
33,673 (5 × 10−8) 0.618 0.621 0.682 0.679 0.680 0.673
33,673 (0.0035) 0.618 0.728 0.762 0.755 0.757 0.742
∞ 0.618 0.820 0.840 0.832 0.835 0.821
In parentheses, P-value thresholds to select SNPs into polygenic score; N cases, number of cases in training sample with 0.99 controls per case as in the Breast Cancer
Association Consortium.
the family-wise type-1 error, that inﬂuences the explanatory
power of the polygenic score.
3.2 Breast cancer
Breast cancer is another disorder for which there is substantial
interest in improving environmental risk scores with SNPs.
Here, the general intention is to more eﬀectively target enrol-
ment on screening programs for early detection, rather than
to directly treat risk factors. Chemoprevention may be recom-
mended for high risk groups. A number of prediction mod-
els have been proposed, including BCRAT (commonly known
at the Gail model) (Gail et al., 1989), IBIS (Tyrer-Cuzick)
(Tyrer, Duﬀy, & Cuzick, 2004), Barlow (Barlow et al., 2006),
Rosner-Colditz (Rosner & Colditz, 1996), and BOADICEA
(Antoniou, Pharoah, Smith, & Easton, 2004). Common risk
factors include age, age at menarche, mutations in BRCA1 or
BRCA2, age at ﬁrst live birth, ﬁrst degree family history, and
history of breast biopsy. Generally speaking these models can
perform well in women at high risk but are less accurate in the
population at large.
In an early eﬀort, Wacholder et al. (2010) estimated the
improvement in the AUC of the Gail model with the addition
of 10 SNPs associated from GWAS. The Gail model achieved
AUC of 0.580, improving to 0.618 with the addition of SNPs.
Subsequently, Darabi et al. (2012) used 18 SNPs to improve
AUC from 0.548 to 0.615 in a Swedish sample. Most recently,
Mavaddat et al. (2015) constructed a polygenic score from
77 SNPs identiﬁed in the largest consortium yet assembled
(Michailidou et al., 2013), obtaining AUC of 0.622 with a
training sample of 33,673 cases and 33,381 controls. In a sim-
ulation study, Garcia-Closas et al. (2014) suggested this could
be improved to 0.670 in combination with an environmental
score with similar components to the Gail model. The envi-
ronmental score alone had AUC of 0.618.
These previous studies did not consider the heritability of
environmental factors such as age at menarche (Elks et al.,
2010) and family history, and thus not the correlation between
genetic and environmental scores. With this sample size,
and again for simplicity assuming a genome-wide panel of
100,000 independent SNPs, the 77 SNP AUC of 0.622 would
be achieved when the chip heritability of breast cancer𝑅2
𝐺𝑌
=
0.3, proportion of null SNPs 𝜋0 = 0.95 and disease preva-
lence 𝐾 = 0.05 with SNPs selected by 𝑃 < 5 × 10−8. With
this prevalence, an AUC of 0.618 would be achieved by an
environmental score with 𝑅2
𝑋𝑌
= 0.0375.
Under these parameters, Table 5 shows expected AUC for
low and high chip heritabilities of the environmental score,
and low andmoderate genetic correlation between disease and
environment. The results for selection by 𝑃 < 5 × 10−8 agree
well with Garcia-Closas et al. Again it is clear that substantial
improvements are possible by more liberal selection of SNPs,
and that further gains will be possible with larger training
samples. Interestingly the results are quite robust to the envi-
ronmental chip heritability𝑅2
𝐺𝑋
and the genetic correlation 𝜌.
Supplementary Table S7 shows results for a higher prevalence
of 0.1, and Supplementary Table S8 for a lower proportion of
null SNPs of 0.8. Figure 4 shows expected AUC as a func-
tion of training sample size. Again, the gains are small even if
the two scores are assumed independent, but the sample size
required to reach a given AUC can depend more strongly on
the genetic correlation. For example, to reach AUC of 0.8, the
required sample size is about 81,000 when 𝑅2
𝐺𝑋
= 0.1 and
𝜌 = 0.1, but 140,000 when𝑅2
𝐺𝑋
= 0.8 and 𝜌 = 0.4. The Breast
Cancer Association Consortium has recently grown to about
120,000 cases, which according to Figure 4 will yield an AUC
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TABLE 6 NRI for a single-risk threshold of 8%, continuous NRI and IDI for combined scores based on a genetic model matching results for
breast cancer reported by Mavaddat et al
8% Risk Continuous NRI IDI
N cases Case Control Case Control
33,673 (5 × 10−8) 0.119 − 0.046 0.286 0.015 0.008
33,673 0.303 (0.0034) − 0.059 (0.89) 0.544 (0.0035) 0.029 (0.0035) 0.034 (0.0035)
∞ 0.441 − 0.094 0.771 0.041 0.089
In parentheses, P-value thresholds to select SNPs into polygenic score; N cases, number of cases in training sample with 0.99 controls per case as in the Breast Cancer
Association Consortium. 𝜌 = 0.4, 𝑅2
𝐺𝑋
= 0.8.
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F IGURE 4 AUC of weighted combined score as a function of
training sample size
Note: Genetic model chosen to match results for breast cancer reported
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not far from the large sample limit. Again, in the near future
these projections will be reﬁned by further prediction studies.
Table 6 shows NRI at a single risk threshold of 8%, which
is the 10-year absolute risk between ages 40–50 above which
chemoprevention is advised in the United Kingdom (National
Institute for Health and Care Excellence, 2013). Again the
optimal SNP selection depends on the criterion optimized.
Addition of SNPs to the Gail model would result in case NRI
of 0.119 and control NRI of −0.046 when selecting SNPs
by 𝑃 < 5 × 10−8, improving to case NRI of 0.303 and con-
trol NRI of −0.059 with more liberal selection. The negative
control NRI implies that more women would be unnecessar-
ily recommended to receive chemoprevention, and because
most women do not develop breast cancer, this translates to
a large absolute number of women. Indeed the speciﬁcity for
the development of cancer is 92% for the environmental score
alone, but is 86% for the combined score, whereas the sensi-
tivities are 16% and 32% respectively. Thus, while AUC and
NRI appear encouraging, a large number of women would in
fact be misclassiﬁed under either score. The continuous NRI
shows that over half of cases are expected to increase their
risk score. Supplementary Tables S9 and S10 show results
for alternative values of the prevalence and proportion of null
SNPs.
Reﬂecting applications in screening, the breast cancer liter-
ature emphasises the proportion of cases present within some
highest-risk proportion of the population (Pharoah, Anto-
niou, Easton, & Ponder, 2008). This is a point on a Lorenz
curve, which resembles the receiver-operator characteristic
curve with speciﬁcity replaced by a population proportion.
For a proportion of the population q at highest risk accord-
ing to score X, the corresponding threshold of liability is√
𝜎2
𝑋
Φ−1(1 − 𝑞) and so the proportion of cases selected by
that threshold is:
1 − Φ
⎛⎜⎜⎜⎝
√
𝜎2
𝑋
Φ−1(1 − 𝑞) − 𝐸(𝑋|𝑌 = 1)√
var(𝑋|𝑌 = 1)
⎞⎟⎟⎟⎠ .
Table 7 shows the proportion of cases within the top 10%,
20%, and 50% of the population at highest risk according to
the environmental score X and the combined score ?̂?𝑐𝑜𝑚𝑏.
These results suggest, for example, that at current sample
sizes nearly half of cases could be detected by screening the
20% of the population with highest combined scores. With
larger training samples, over 90% of cases might be detected
by screening the half of the population with highest scores.
These results are compatible with those of previous studies
(Garcia-Closas et al., 2014; Pharoah et al., 2008). Supple-
mentary Tables S11 and S12 show results for alternative val-
ues of the prevalence and proportion of null SNPs. Similar to
other sensitivity analyses in the supplementary tables, these
yield modest quantitative changes with similar qualitative
conclusions.
3.3 Height
Here the example of height is used to illustrate a relation-
ship between a polygenic score and family history. Of course,
family history is an environmental risk factor for any heri-
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TABLE 7 Proportion of cases present among highest risk quantiles in the population under a geneticmodelmatching results reported inMavaddat
et al
Top 10% Top 20% Top 50%
N cases Polygenic Env Comb Polygenic Env Comb Polygenic Env Comb
33,673 (5 × 10−8) 18.8 18.5 22.2 33.0 32.7 37.7 66.2 65.7 71.1
33,673 (0.0035) 29.8 18.5 30.7 47.6 32.7 48.7 79.9 65.7 80.9
∞ 43.0 18.5 43.0 63.1 32.7 63.1 90.5 65.7 90.5
Polygenic: polygenic score alone; Env: environmental score alone; Comb: least squares weighted sum; in parentheses: P-value thresholds to select SNPs into polygenic
score; N cases: number of cases in training sample with 0.99 controls per case as in the Breast Cancer Association Consortium.
G
X
Y
F
F IGURE 5 Directed acyclic graph showing correlation between
polygenic and environmental scores arising from family history
A simpliﬁed scenario is shown in which there are no shared environ-
mental eﬀects. G: polygenic score; F: polygenic scores of other family
members; X: family history; Y: outcome.
table condition, but it will be correlated with the measured
genetic risk. An initial challenge for any genetic predictor is to
exceed the predictive accuracy of family history (Do, Hinds,
Francke, & Eriksson, 2012). For example, Aulchenko et al.
(2009) showed that 54 associated SNPs could not predict an
individual's height as accurately as could the mean height of
its parents. Through simulation they showed that a gene score
explaining all the heritability could predict better than the
family history. A natural question is: what sample size would
allow development of a gene score with predictive accuracy
better than the family history?
Figure 5 is a directed acyclic graph showing a simpliﬁed
situation in which the family history is entirely explained
by genetics. Although in many cases shared environment
also contributes to family history, this graph may be fairly
appropriate for height because it is highly heritable and par-
ents have often reached their full stature before produc-
ing oﬀspring. Under this structure, the parameters of the
quantitative model may be derived exactly in terms of the
heritability.
Assume the commonly used value of 80% for the heritabil-
ity of height. Under an additive model, the height of a child
is the sum of genetic contributions from mother and father
and of unique environmental contributions. It is easy to show
that the genetic covariance between the child and the mean-
parents is half the heritability, and then that the genetic corre-
lation, 𝜌 = 1√
2
. Furthermore the variance in child explained
by the mean-parents is twice the square of the covariance,
so 𝑅2
𝑋𝑌
= 0.32, which is taken as the predictive accuracy of
the family history. Finally, the chip heritability of the mean-
parents is half the chip heritability, 𝑅2
𝐺𝑋
= 12𝑅
2
𝐺𝑌
.
The GIANT consortium has conducted discovery meta-
analyses for height, which despite very large samples have yet
to exceed the predictive accuracy of family history. A discov-
ery sample of approximately 134,000 achieved R2 of 13.3%
by selecting SNPs with P < 5 × 10−4 (Lango Allen et al.,
2010); a larger study of approximately 250,000 improved only
to R2 of 17% with P < 5 × 10−5 (Wood et al., 2014). These
studies used a densely imputed panel of 2.5 M SNPs with
chip heritability estimated within contributing studies at 60%
of the total heritability, so 𝑅2
𝐺𝑌
= 0.6 × 0.8 = 0.48. Stepwise
regressions were used to estimate SNP weights, so the esti-
mated eﬀects may be considered approximately independent
across all 2.5 M SNPs. Across six polygenic scores with dif-
ferent selection thresholds, the best ﬁtting model (Palla &
Dudbridge, 2015) has chip heritability 𝑅2
𝐺𝑌
= 0.34 and pro-
portion of null SNPs 𝜋0 = 0.996. This consortium level esti-
mate of 𝑅2
𝐺𝑌
is lower than the study-level estimates of 0.48,
as has previously been observed (Yang et al., 2015). This is
likely due to heterogeneity in data management across stud-
ies, if not actual genetic heterogeneity, and can be accounted
for by estimating the genetic covariance between training
and target data as a free parameter separately from the chip
heritability in the training data (Palla & Dudbridge, 2015).
This yields a genetic covariance of 0.46 with 𝜋0 = 0.995;
the estimate of 𝑅2
𝐺𝑌
is 1, but this is a known artifact of this
method, which has little bearing on estimates of predictive
accuracy. Under this model, the prediction R2 is 0.21 with
an inﬁnite training sample, implying that the consortium-
based estimate can never predict as well as the family
history.
This alarming result is mitigated by considering a homoge-
neous training sample in which we assume 𝑅2
𝐺𝑌
= 0.48, with
𝜋0 = 0.995 as estimated above and perfect genetic correla-
tion with the target sample. Then R2 > 0.32 when the train-
ing sample exceeds 301,000 subjects. Emerging datasets such
as UK Biobank will soon allow such predictions to be tested
empirically.
Under this model, Figure 6 shows the accuracy of a com-
bined score as a function of training sample size, showing
that the family history continues to provide useful information
even as the polygenic risk becomes more informative. This is
not surprising, as the chip heritability falls short of the total
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heritability, which can be accessed, albeit imperfectly, by the
family history. Nevertheless, this vignette demonstrates that
an independent eﬀect of family history is consistent with it
being entirely genetic in origin, as long as the genetic predictor
is not complete. Furthermore, it is apparent that for strongly
heritable traits, the high threshold of predictive accuracy set
by family history can only be overcome through very large
and homogeneous genetic discovery studies.
4 DISCUSSION
Accurate genetic prediction of disease risk remains an elusive
goal, but its importance is evident from an increasing number
of studies evaluating its potential for many traits. In conjunc-
tion with existing environmental predictors, the incremen-
tal beneﬁt of polygenic scores has appeared modest to date.
The results presented here allow an informed interpretation
of observed results and anticipation of future results as larger
training datasets are assembled. In particular, it is clear that
at current sample sizes predictive accuracy, and incremental
beneﬁt, could be substantially improved by including SNPs at
liberal signiﬁcance thresholds. Furthermore, for chip correla-
tion up to 0.4, the degree of correlation and the heritability of
the environmental score have little bearing on predictive accu-
racy. These results are encouraging for practice because they
reduce concern about accounting for the heritable compo-
nents of environmental scores. In particular, it seems accept-
able to combine consortium estimates of marginal SNP eﬀects
with environmental risk scores, rather than jointly estimating
conditional SNP and environmental eﬀects in training sam-
ples that may be much smaller than those of consortia.
The majority of studies to date have restricted their poly-
genic scores to genome-wide signiﬁcant SNPs, but this is sub-
optimal. One justiﬁcation has been that genotyping a limited
number of SNPs is more cost-eﬀective than a whole-genome
panel; but this should be viewed in the context of potentially
predicting multiple conditions from a single DNA sample, for
which genome-wide typing will be more eﬃcient. Another
view is that it is diﬃcult to argue for inclusion of individual
risk factors (here SNPs) that have but weak evidence of asso-
ciation. However, by viewing the polygenic risk as a single
entity, this argument becomes irrelevant; the role of individ-
ual SNPs then applies only to how that risk is calculated.
The present work uniﬁes previous work of So and Sham
(2010), who showed how many common measures of pre-
dictive accuracy can be expressed in terms of liability R2,
with that of Dudbridge (2013), who allowed for ﬁnite train-
ing samples and selection of SNPs into the polygenic score.
Only the most commonly reported measures are considered
here, namely AUC, NRI, and IDI, but other measures, such as
those related to predictiveness curves (Pepe et al., 2008) and
net beneﬁt (Baker, 2009), could be treated in the samemanner.
In contrast to some previous approaches, the genetic covari-
ance between environmental score and predicted trait is con-
sidered here explicitly, along with unweighted and weighted
combinations of genetic and environmental scores. Although
the genetic covariance is the key property, the results are
presented in terms of genetic correlation and variances, as
these quantities can be estimated readily by existing methods
(Bulik-Sullivan et al., 2015; Lee et al., 2012).
The modest eﬀect of genetic correlation on AUC is not
too surprising, because AUC depends on ranking the scores
rather than their absolute values, but more surprisingly the
NRI, which does depend on absolute risk, is also quite robust
to correlation. Higher levels of correlation will of course tend
toward no incremental beneﬁt, but such scenarios are arguably
unlikely because most environmental scores include nonheri-
table factors such as age, as well as the environmental compo-
nent of the heritable factors. Nevertheless, the predictive accu-
racy can be improved by accounting for covariance between
genetic and environmental predictors. Furthermore, the level
of correlation can have more substantial eﬀects on the sample
size required to reach a prespeciﬁed level of accuracy.
The NRI has been criticized on theoretical and practical
grounds (Kerr et al., 2014; Pepe et al., 2015), yet it has an
intuitive appeal that should not be overlooked. An important
recommendation is that it should be reported separately for
cases and controls, especially if they are associated with dif-
ferent costs (Pencina et al., 2011). Here, it has been shown
that for given training data, the optimal polygenic score dif-
fers for case NRI and control NRI, and also varies with risk
thresholds. Because in a prospective setting one cannot know
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who is a case, the polygenic score must be deﬁned according
to a criterion based on relative costs of case and control NRI.
Such considerations will further complicate reporting of NRI
in evaluation studies, although this problem does not apply to
the continuous NRI or IDI.
We have focused on two commonly reported measures,
AUC and NRI, yet both measures have been severely crit-
icized and there is a recognized need for more appropriate
measures of incremental beneﬁt. For example, stratiﬁcation
of the population by genetic risk may allow more eﬃcient
application of environmental risk scores. In CVD, a group at
high genetic risk attained 20% estimated risk at an age up to
18 years younger than the low genetic risk group (Abraham
et al., 2016). In breast cancer, the absolute risk associated with
modiﬁable risk factors was signiﬁcantly higher amongwomen
in the top decile of nonmodiﬁable risk (including 92 SNPs)
compared to those in the lowest decile (Maas et al., 2016).
These results suggest that even limited genetic data can pro-
vide useful stratiﬁcation for identifying subjects who would
beneﬁt most from intervention. Such perspectives oﬀer amore
optimistic view of genetic prediction that will only become
stronger with larger training samples and more liberal selec-
tion of genetic markers.
Consortium studies are now approaching the sizes at which
useful levels of predictive accuracy are predicted by theory.
However, such results have not yet been achieved in practice.
One clear reason is that many studies have restricted their
polygenic scores to genome-wide signiﬁcant SNPs. Given
the large size of the CARIODoGRAMplusC4D consortium,
higher levels of accuracy should be possible by including
more SNPs in the risk score. This has been demonstrated by
Abraham et al. (2016), although their approach of pruning the
full set of SNPs may be suboptimal. Furthermore, accurate
odds ratios are currently available only for a targeted array
product, the MetaboChip, further limiting the accuracy that
can be achieved. Therefore their results, which are intermedi-
ate between those using genome-wide signiﬁcant SNPs and
those predicted here, seem consistent with the present the-
ory. The present work suggests that as genome-wide typing is
completed on a larger number of studies, more accurate pre-
diction will be achieved by highly polygenic scores.
The Breast Cancer Association Consortium too is
approaching a suﬃciently large number of cases. To date,
consortium-wide genotypes have only been generated on the
iCOGS platform, another targeted array focused on candidate
genes for certain cancers. Again therefore, prediction studies
have focused on genome-wide signiﬁcant SNPs, but the next
generation of targeted arrays, which include a genome-wide
backbone, oﬀer greater promise for developing more accurate
polygenic scores.
Given the large size of the GIANT consortium, the contin-
uing modest prediction of height is surprising but could be
explained by heterogeneity between consortium-level train-
ing data and individual target studies. The source of this
heterogeneity remains unclear (Yang et al., 2015), but with
the emergence of large, homogeneous datasets such as UK
Biobank, more accurate genetic predictors could be developed
that exceed the predictive accuracy of the family history.
An alternative explanation is that the present model for
genetic eﬀects, consisting of a mixture of a normal distribu-
tion and a mass at zero, is incorrect for this phenotype. If
in fact the true distribution had a sharp peak at zero, then
the present model could ﬁt the data well, but the individual
SNP eﬀects would be more dispersed and thus harder to esti-
mate en masse. Such a model could apply, for example, to
schizophrenia, for which ﬁne-scale heritability analyses sug-
gest an extremely polygenic architecture (Loh et al., 2015),
while the best ﬁtting normal-null mixture estimates a null pro-
portion of around 90% (Palla & Dudbridge, 2015). Although
theory based on a mixture of exponential distributions (Chat-
terjee et al., 2013) has roughly agreed with the normal-null
mixture, there is a notable exception in the case of height,
for which a mixture of three exponentials ﬁts GIANT data
well with chip heritability at 45%. This ﬁtted model projects
that prediction R2 will not exceed 0.32 until the training sam-
ple size exceeds one million, in contrast to our projection of
301,000 for a homogeneous sample. Finally, departures from
the additive model may lead to a poor ﬁt of the polygenic
score.
The substantial heritability of most common disorders
implies that clinically useful prediction can be achieved when
the heritable risk is accurately measured. The present results
suggest that such results may not be too far oﬀ in terms of
discovery sample size. As that level is approached, the poly-
genic score dominates the prediction compared to existing
environmental scores, although the dynamic and potentially
modiﬁable nature of environmental factors ensures that they
will continue to play a crucial role in assessing absolute risk.
Such predictors may include epigenetic or other “omic” fac-
tors that themselves are selected from high dimensional pan-
els. The present work assumes a known, low dimensional risk
factor whose eﬀect on outcome is known precisely. Extension
to high dimensional, dynamic nongenetic predictors, allowing
for simple model selection as in the polygenic score, will be
pursued in subsequent work.
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